DelMar Pharmaceuticals Inc. (NASDAQ:DMPI) went up by 8.59% during the previous trading session, and it is maintaining the win ahead of Tuesday’s trading session. The share price of the Biotechnology giant went up by $0.70 to trade ended Tuesday trading at $0.64. This is up from the $0.6446 price recorded on Monday’s trading session. Thanks to this latest performance, DMPI is closer to the higher price 52-week target of $4.00 and further from the lowest price target of $2.00. Its performance from the start of the year has also been positive, with DMPI up by 1.49% year-to-date.
DelMar Pharmaceuticals Inc. (DMPI) started the day trading at $0.6614 and recorded an intraday high of $0.729. It also recorded an intraday low of $0.6446 during Tuesday’s trading session. DelMar Pharmaceuticals Inc. is a very active stock that recorded a trading volume that is less than -156.42% of the average daily trading volume on Tuesday. The stock’s trading volume on Tuesday was 247587, which is less than -156.42 of the total average daily trading volume of 634.86K.
DelMar Pharmaceuticals Inc. (NASDAQ:DMPI) 2020 Performance Impressive
The increase in DMPI’s stock price on Tuesday saw its overall performance boost over the past few months. We can quantify the performance of the stock so far this year using a few metrics. The 52-week high price of DMPI currently stands at $2.66, which is higher than the current trading price of the stock by 73.68%. However, DMPI’s current trading price is -84.21% lower than the 52-week low price of $0.38. In terms of trading volume, DelMar Pharmaceuticals Inc. currently experienced healthy participation during the last trading session. 247587 shares of DelMar Pharmaceuticals Inc. were traded on the stock exchange on Tuesday, which is less than -156.42% of the 634.86K average trading volume of the stock.
The performance of the stock has been positive over the past year. DMPI’s performance over the past one year has seen it plunge by -53.02%, while the stock has gone up by 10.55% in the last six months. The quarterly performance of DMPI currently stands at 62.72%, and it is down by -33.96% in the last month. The only positive figure was from the weekly performance, which currently reads 3.69%. At the time of writing DMPI’s report, the company has a total market cap of $8.58M, making it one of the largest publicly-traded companies in the world.DelMar Pharmaceuticals Inc. also has over 4 employees all over the world.
DMPI Insider Activities
For DelMar Pharmaceuticals Inc., insiders hold 1.90% of all company shares. The insider transactions over the past six months are down by 0.00%. During that period, insiders bought 152 shares in 8 transactions. In that same period, insiders sold 16 of their shares in 2 transactions. After these transactions, insiders at DelMar Pharmaceuticals Inc. now hold 164.81k shares, which is over 12.46% of the total company stocks. Institutional investors currently hold a large chunk of the DMPI shares, as they control 1.44% of the company’s total stock.
DMPI Fundamental Analysis
For DelMar Pharmaceuticals Inc., the stock’s diluted earnings per share (EPS) stands at -1.41. In the coming year, analysts expect the EPS to be -0.46. The stock’s EPS growth this year is 41.80%, -22.90% in the previous five years. In terms of revenue, DelMar Pharmaceuticals Inc.’s quarterly sales (YOY) is shrinking at -0.12, which is higher than the average annual revenue of -22.90% over the past half a decade.
DMPI Technical Analysis
The Simple Moving Average (SMA) is one of the most powerful technical indicators. The 20-day Simple Moving Average of DMPI currently stands at -23.52%, while the SMA50 is -12.65%. The biggest one is the SMA200, which is currently reading 11.95% ahead of Tuesday’s trading session. The Relative Strength Index of this stock is 42.45.